Title: Integration of single-cell and bulk RNA sequencing to establish a prognostic signature
based on tumor-associated macrophages in colorectal cancer
Version: 2 Date: 02 Oct 2023
Reviewer's report:
The manuscript by Hua Li and colleagues presents M2-like TAM-associated prognostic
signature.  It is interesting but still has some drawbacks as follows.
1. Your risk score was significantly correlated with overall survival. Is there a significant
difference between high- and low-risk groups in the survival analyses divided into different
subgroups according to their tumor stage, pathologic M stage, etc.?
2. Also, would there be a significant difference in DFS, etc.?
3. In this study, authors reveal that relationship between the risk score and anticancer drug
sensitivity. Did you analyze other drugs and find significant differences only in the four listed
drugs?
Title: Integration of single-cell and bulk RNA sequencing to establish a prognostic signature
based on tumor-associated macrophages in colorectal cancer
Version: 2 Date: 02 Oct 2023
Reviewer's report:
The manuscript by Hua Li and colleagues presents M2-like TAM-associated prognostic
signature.  It is interesting but still has some drawbacks as follows.
1. Your risk score was significantly correlated with overall survival. Is there a significant
difference between high- and low-risk groups in the survival analyses divided into different
subgroups according to their tumor stage, pathologic M stage, etc.?
2. Also, would there be a significant difference in DFS, etc.?
3. In this study, authors reveal that relationship between the risk score and anticancer drug
sensitivity. Did you analyze other drugs and find significant differences only in the four listed
drugs?
Please review this paper.
user
Title: Integration of single-cell and bulk RNA sequencing to establish a prognostic signature
based on tumor-associated macrophages in colorectal cancer
Version: 2 Date: 02 Oct 2023
Reviewer's report:
The manuscript by Hua Li and colleagues presents M2-like TAM-associated prognostic
signature.  It is interesting but still has some drawbacks as follows.
1. Your risk score was significantly correlated with overall survival. Is there a significant
difference between high- and low-risk groups in the survival analyses divided into different
subgroups according to their tumor stage, pathologic M stage, etc.?
2. Also, would there be a significant difference in DFS, etc.?
3. In this study, authors reveal that relationship between the risk score and anticancer drug
sensitivity. Did you analyze other drugs and find significant differences only in the four listed
drugs?
assistant